The findings indicated that VX-11e, AKT inhibitor VIII, AT-7519, BMS345541, Bortezomib, CP466722, FMK, and JNK-9L exhibited greater effectiveness in treating low-risk HCC patients, implying potential benefits for this specific group of patients. The gene discussed is AKT1; the disease is hepatocellular carcinoma.